Arbaclofen placarbil
Arbaclofen placarbil (/ɑːrˈbækloʊfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]
Clinical data | |
---|---|
Pregnancy category |
|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.221.150 |
Chemical and physical data | |
Formula | C19H26ClNO6 |
Molar mass | 399.87 g·mol−1 |
3D model (JSmol) | |
| |
|
It is being developed as an addiction medicine to treat alcoholism. [2]
See also
References
- "Archived copy". Archived from the original on 2013-12-02. Retrieved 2013-06-03.CS1 maint: archived copy as title (link)
- "Pill that replaces alcohol aims to end 'glass of wine' craving".
H2 antagonists ("-tidine") | |
---|---|
Prostaglandins (E)/analogues ("-prost-") | |
Proton-pump inhibitors ("-prazole") | |
Potassium-competitive acid blockers ("-prazan") |
|
Others | |
Combinations | |
|
Ionotropic |
| ||||
---|---|---|---|---|---|
Metabotropic |
| ||||
|
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
See also: Receptor/signaling modulators • Transient receptor potential channel modulators |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.